



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/069,950	03/07/2002	Sophie Gaubert	02043	2908

23338 7590 06/18/2004

DENNISON, SCHULTZ, DOUGHERTY & MACDONALD
1727 KING STREET
SUITE 105
ALEXANDRIA, VA 22314

EXAMINER

KISHORE, GOLLAMUDI S

ART UNIT PAPER NUMBER

1615

DATE MAILED: 06/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/069,950	GAUBERT ET AL.	
	Examiner	Art Unit	
	Gollamudi S Kishore, PhD	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 16-34 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 16-34 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>3-7-2002</u> . | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

The preliminary amendments dated 3-7-02 and 3-20-02 are acknowledged.

Claims included in the prosecution are 16-34.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 19-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

'said immunoglobulins' on last line claim 19 has no antecedent basis.

Furthermore, this claim is drawn to a method of producing IgA and what is recited on the last line of this claim is the purification of immunoglobulins and not IgA. Similar is the case with claim 20.

What is being conveyed through claim 20? The claim is drawn to a method of treating a human. How can removing and purifying immunoglobulins result in the treatment? The last line of the claim recites such a limitation. Furthermore, it is unclear as to what the human is treated for.

'mucosal' is misspelled in claim 21.

The distinction between cholesterol derivatives and cholesterol esters as recited in claim 29 is unclear. Esters are derivatives.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this

Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. Claims 16-17 are rejected under 35 U.S.C. 102(b) as being anticipated by Haan et al (Vaccines 13, no. 2, pp. 155-162, 1995.

Haan et al teach intra-nasal administration of multilamellar vesicles containing influenza viral sub-units; according to Haan et al

such an administration results in an induction of both systemic IgG and secretory IgA responses compared with the antigen alone. The liposomes are made from the phospholipids which are either saturated or unsaturated and contain in addition cholesterol (abstract, Materials and Methods and Discussion section). Multilamellar liposomes have onion like structure with concentric lipid bilayers separated by aqueous medium. The reference thus, meets the requirements of instant claims.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 20-27, 31 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haan et al (Vaccines 13, no. 2, pp. 155-162, 1995 by itself or in combination with Doerschuk (5,702,946).

Haan et al do not teach the purification of the immunoglobulins. However, since purification of antibodies is well known in the art, it is deemed obvious to purify the immunoglobulins if the purification is necessary. One of ordinary skill in the art would be motivated to purify the immunoglobulins if necessary since such techniques are conventional as taught by Doerschuk (col. 9, lines 25-30). Haan does not specifically teach the percent encapsulation of the antigen. However, since this amount depends upon the initial amount of added antigen, it is deemed to be a manipulatable parameter.

7. Claims 16-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haan et al (Vaccines 13, no. 2, pp. 155-162, 1995) by itself or in combination with Doerschuk (5,702, 946) in further combination with Roux (5,908,697).

As pointed out above, Haan et al teach that intra-nasal administration of multilamellar vesicles containing influenza viral sub-units

Art Unit: 1615

Results in an induction of both systemic IgG and secretory IgA responses compared with the antigen alone (abstract, Materials and Methods and Discussion section).

Roux discloses active principle carriers containing lecithin (phospholipid) and sucrose ester and the other surfactants. The structures disclosed by Roux are multilamellar vesicles with an onion like structure having an internal liquid crystal structure formed by a stack of concentric bilayers. According to Roux, these vesicles have certain advantages, which include less sensitivity to bacterial contamination. The vesicles have diameters of 0.1 and 50 microns. The two surfactants according to Roux have HLB values between 3 and 7 and 8-15 respectively (abstract, col. 3, lines 4-27; col. 5, line 40 through col. 7, line 40; Examples and claims). What are lacking in Roux are the teachings of using an antigen as active principle and mucosal administration of the composition to elicit an immune response.

As discussed above, multilamellar liposomes have onion like structure with concentric lipid bilayers separated by aqueous medium. Assuming that Haan's multilamellar liposomes are different from instant liposomes, it is deemed obvious to use multi-lamellar liposomes containing lecithin and sucrose esters of Roux would have been obvious to one of ordinary skill in the art because of the advantages taught by Roux. Alternately, the use of antigen as the active principle and administer the composition of Roux mucosally, with a reasonable expectation of success, since the reference of

Haan shows the enhancement of immune response when antigens are administered mucosally in multi-lamellar liposomes compared to antigen alone.

8. Claims 16-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wassef et al (Immunomethods, 4, pp. 217 222, 1994) in combination with Haan et al (Vaccines 13, no. 2, pp. 155-162, 1995) by itself or in combination with Doerschuk (5,702, 946) and Roux (5,908,697) both cited above.

Wassef et al teach the successful use of multilamellar vesicles as carriers for vaccines (note abstract, pages 218-220).

Wasseff et al although teach that liposomal vaccines have been administered by many routes, they do not specifically teach mucosal route of administration.

Wassef et al's disclosure also lacks specifics about multilamellar vesicles.

The teachings of Haan et al, and those of Doerschuk, and Roux have been discussed above.


The use of Roux's multilamellar vesicles for encapsulating an antigen and delivering the composition mucosally would have been obvious to one of ordinary skill in the art because of the advantages of such liposomes taught by Roux and the enhancement of the immune response when administered mucosally as seen from Haan et al.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S Kishore, PhD whose telephone number is (571) 272-0598. The examiner can normally be reached on 6:30 AM-4 PM, alternate Friday off.

Art Unit: 1615

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Gollamudi S Kishore, PhD
Primary Examiner
Art Unit 1615

GSK